As seniors become frustrated and Part D enrollment lags, drug benefit plans cannot grow fast enough to manage risk. Some leave the market, and others cut benefits.
Jason Pesile
Advertisement
Articles by Jason Pesile
Advertisement
Latest Updated Articles
Medicare Part D: D for Doomed?Published: May 1st 2006 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
Could DTC Programs Help Simplify the Drug-Pricing System?
5
